-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-WALTHAM, Mass.,...
Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder...
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion...
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to...
agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists...
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent...
MILAN, Italy, May 11, 2023 (GLOBE NEWSWIRE) -- The Italy Healthcare Innovation Summit, an event organized by Bamberg Health, attracted...
DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...
Celularity has been advised by the Tamer Group to expect at least $60 million to $80 million in 2023 purchase...
SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics marketSHANGHAI and BOULDER, Colo., May 10, 2023 (GLOBE...
BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel...
FREDERICK, Md., May 10, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Adial to receive potential development and commercial milestone payments of up to $83 million on the first three compounds plus...
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30...
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
- Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term...
- FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA)...
Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third...